Abstract 107P
Background
Tumor stroma consists of a complex network of safeguards for tumor proliferation. Tumour stromal imaging using fibroblast-activated protein-tagged radionuclide provides a metabolic-radiological quantum of tumor stromal content. Tumors rich in stroma have been traditionally associated with poorer disease-free outcomes. Our study correlates between standard uptake values (SUV) in fibroblast imaging to tumor stromal ratio evaluated pathologically and the response to radiation therapy in locally advanced carcinoma rectum.
Methods
50 patients of carcinoma Rectum with all patients having undergone cancer associated Fibroblast PET CT scan prior to starting neoadjuvant chemoradiation. Tumors having SUV max > 10 were considered as High. Metabolic activity in tumor site was compared to Tumor stromal ratio and response to radiation was evaluated in histopathological report. Patients were classified into High TSR (<50% Stromal content) and Low Tumor Stroma Ratio (>50% Stromal content).
Results
7 patients who had complete pathological response all had high TSR and SUV mean 20.4. 34 patients had <50% residual disease 67% had high TSR and SUV mean 17.6 and 34% had low TSR and SUV mean of 21.44. 9 patients had >50% residual disease had 77% low TSR and high SUV mean 25.11(Range- 9.51-92.33). Patients with both Low TSR [ >50% stromal content] and SUV Max > 10 have poor pathological response compared to patients with low TSR. In the low stromal content irrespective of SUV the local control was good. Table: 107P
| High TSR | Low TSR | High SUV | Low SUV | |
| Complete response | 7(32%) | 0 | 4(15.4%) | 3(12.5%) |
| <50% Residual disease | 23(71.8%) | 11(61%) | 14(53.8%) | 20(83.3%) |
| >50% Residual disease | 2(6.2%) | 7(39%) | 8(30.8%) | 1(4.2%) |
Conclusions
High Tumor Stromal Ratio showed better complete and partial response to neoadjuvant chemoradiation in locally advanced carcinoma rectum. Tumors with high stromal content were observed to have higher SUV values in fibroblast stromal imaging and the same were also more commonly associated with suboptimal response. The need for dose escalation for the same has to be explored for better tumor control.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
485P - LDCT lung cancer screening of never-smokers meta-analysis subgroup analysis: Adenocarcinoma is the highly predictive histology identified in never-smokers
Presenter: Sai-Hong Ou
Session: Poster Display
Resources:
Abstract
486P - Fiscal feasibility and implications of integrating lung cancer screening into Hong Kong’s healthcare system
Presenter: Herbert Ho Fung Loong
Session: Poster Display
Resources:
Abstract
487P - Evaluating the performance of the USPSTF lung cancer screening guidelines in an Asian population of lung cancer patients
Presenter: Jian Wei Tan
Session: Poster Display
Resources:
Abstract
488P - Pulmonary ground glass opacity lesions: Immune ecosystem and its clinical relevances of early-stage lung adenocarcinoma
Presenter: Shensi Shen
Session: Poster Display
Resources:
Abstract
489TiP - BGB-LC-202 (NCT05577702): Phase II Umbrella study of tislelizumab (TIS) monotherapy and TIS-based immunotherapy combinations +/- chemotherapy (CT) as neoadjuvant treatment in Chinese patients (pts) with resectable stage II to IIIA non-small cell lung cancer (NSCLC)
Presenter: Wentao Yu
Session: Poster Display
Resources:
Abstract
491P - Furmonertinib as adjuvant therapy for elderly patients in resected EGFR-mutated non-small cell lung cancer: A double-center, real-world experience
Presenter: Ziheng Wu
Session: Poster Display
Resources:
Abstract
492P - Penpulimab-based combination neoadjuvant/adjuvant therapy for patients with resectable locally advanced non-small cell lung cancer: Preliminary results from a phase II study (ALTER-L043)
Presenter: Changli Wang
Session: Poster Display
Resources:
Abstract
493P - The prognostic value of 4L lymph node dissection in left-sided operable non-small cell lung cancer: A systematic review and meta-analysis
Presenter: Lei Peng
Session: Poster Display
Resources:
Abstract
495P - Intrinsic STING of CD8+T cells regulates self-metabolic reprogramming and exerts anti-tumor effects
Presenter: Qiuli Xu
Session: Poster Display
Resources:
Abstract
496P - Fruquintinib plus sintilimab in patients (pts) with advanced non-small cell lung cancer (NSCLC) with PD-L1-positive expression: A multicenter, single-arm phase II study
Presenter: Shun Lu
Session: Poster Display
Resources:
Abstract